From these experiments, we conclude that PD-L1–CAR can play a supportive role for other solid tumor-targeted CARs by eliminating the reactive PD-L1-positive cells, if applied sequentially after the tumor-specific CAR, even in a low E:T ratio. This evidence concerns the gene CD274 and neoplasm.